Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.11.072
Abstract: Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol-lowering treatment. Data from over… read more here.
Keywords: pcsk9 inhibitors; ldl cholesterol; lipid modifying; modifying agents ... See more keywords
Effects of blood lipids and lipid‐modifying drugs on intracranial aneurysms
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15471
Abstract: We used two‐sample Mendelian randomization (MR) to examine the effects of blood lipids and lipid‐modifying drugs on intracranial aneurysm (IA). read more here.
Keywords: drugs intracranial; lipids lipid; effects blood; blood lipids ... See more keywords
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16050750
Abstract: The past few years have shown an ongoing interest in lipoprotein(a) (Lp(a)), a lipid molecule that has been proven to have atherogenic, thrombogenic, and inflammatory properties. Several lines of evidence, indeed, have demonstrated an increased… read more here.
Keywords: effects lipid; clinical implications; drugs lipoprotein; potent clinical ... See more keywords